Lisa M. Rimsza, MD
University of Arizona, Tucson, AZ
Dr. Rimsza’s program, as a component of the Lymphoma and Leukemia Molecular Profiling Project (LLMPP), will design and validate multi-analyte diagnostic and prognostic assays to differentiate aggressive B-cell non-Hodgkin’s lymphoma into prognostic groups. The tissue samples will be formalin-fixed and paraffin-embedded (FFPE) and the data generated will be submitted for regulatory review with the intention of establishing a highly accurate standardized diagnostic test with prognostic indicators for widespread clinical use. The ability to distinguish prognostic subgroups will enable the development of therapeutic agents to improve outcomes for patients with the most aggressive forms of this disease.
This international project team includes investigators from the University of Arizona, National Cancer Institute, University of Rochester Medical Center, University of Nebraska Medical Center, Oregon Health and Science University, Cleveland Clinic, Fred Hutchinson Cancer Research Center, BC Cancer Agency (British Columbia, Canada), Oslo University Hospital, the University of Wurzburg, Robert-Bosch-Hospital Stuttgart (Germany), Clinic Corporacio Sanitaria (Spain), Institut Catala d’Oncologia (France), Affymetrix, High Throughput Genomics, Inc., and Nanostring Technologies.
The earlier studies that produced the algorithms of interest to this project were done on frozen tissues provided by 8 LLMPP tissue banks. The same banks will provide, as available, matched FFPE specimens for this study.
Develop a multi-analyte diagnostic and prognostic test for aggressive B cell lymphomas using FFPE lymphoma biopsies